09:45 AM EST - Eupraxia Pharmaceuticals Inc. : Announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week Annual Meeting 2024. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $3.95.
